Incyte settles Rux royalty dispute with Novartis for $280m
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
SENTRY P3 "accruing and approaching its goal"
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Novartis vs. Incyte settle $500m missing rux royalties dispute
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
SOBI's CEO on Q1 call talks M&A
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Drs. Kathleen Moore & Scott Joradan review SEINDO & EC-042
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Dr. Debra Richardson presents a subgroup analysis of the SIENDO trial
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Antengene Announces Intention To Conduct On-Market Share Repurchase April 07, 2025
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Incyte vs. Novartis lawsuit cont'd
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
SOBI's CEO comments on BD M&A (Q2 2024 vs. Q4 2024)
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Dr. Kathleen N. Moore on Xport-EC-042
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Selinexor’s Immunomodulatory Impact in Advancing MM Treatment
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Mgmt not attending Leerink & Barclays conferences?
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Antengene gets selinexor Approved in Indonesia for R/R MM
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Incyte head of R&D discusses their BET inhibitor & says Novartis will need to do a completely new study for Pelabresib
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
$INCY CEO daughter Gynecologic oncologist Dr. Claire Marie Violaine Hoppenot (ahem)
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Geron enrollment slowing down?
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Bluebird Bio sold...
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Life Science fund Catalio Capital Mgmt jump in...
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Antengene Announces XPOVIO® Approved for Insurance Coverage in Taiwan, Benefiting More Patients with R/R MM in the Region
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Dr. Mascarenhas - Seli in MF as SA or DA, 1L or 2L?
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Xport-EC-042 control arm fix?
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Dr. Tilley Jenkins Vogel on Xport-EC-042
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Endometrial Cancer Market Size to Reach USD 31.2 Billion by 2035
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way